Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data

PURPOSE: To evaluate the impact of including a medicine in the list of medicinal products subject to additional monitoring (AM) on the reporting of adverse drug reactions (ADRs) in the european economic area (EEA). METHODS: Interrupted time series using the monthly number of EEA ADR reports in Eudra...

Descripción completa

Detalles Bibliográficos
Autores principales: Segec, Andrej, Slattery, Jim, Morales, Daniel R., Januskiene, Justina, Kurz, Xavier, Arlett, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898803/
https://www.ncbi.nlm.nih.gov/pubmed/33197106
http://dx.doi.org/10.1002/pds.5174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898803/
https://www.ncbi.nlm.nih.gov/pubmed/33197106
http://dx.doi.org/10.1002/pds.5174

Ejemplares similares